Engineered exosomes as a prospective therapy for diabetic foot ulcers

Abstract

Diabetic foot ulcer (DFU), characterized by high recurrence rate, amputations and mortality, poses a significant challenge in diabetes management. The complex pathology involves dysregulated glucose homeostasis leading to systemic and local microenvironmental complications, including peripheral neuropathy, micro-and macro-angiopathy, recurrent infection, persistent inflammation and dysregulated re-epithelialization. Novel approaches to accelerate DFU healing are actively pursued, with a focus on utilizing exosomes. Exosomes are natural nanovesicles mediating cellular communication and containing diverse functional molecular cargos, including DNA, mRNA, microRNA (miRNA), lncRNA, proteins, lipids and metabolites. While some exosomes show promise in modulating cellular function and promoting ulcer healing, their efficacy is limited by low yield, impurities, low loading content and inadequate targeting. Engineering exosomes to enhance their curative activity represents a potentially more efficient approach for DFUs. This could facilitate focused repair and regeneration of nerves, blood vessels and soft tissue after ulcer development. This review provides an overview of DFU pathogenesis, strategies for exosome engineering and the targeted therapeutic application of engineered exosomes in addressing critical pathological changes associated with DFUs.

Keywords

Diabetic foot / Foot ulcer / Engineered exosomes / Diabetic angiopathy / Diabetic peripheral neuropathy / Wound infection / Inflammation / Re-epithelialization / Wound healing

References

[1] Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.

[2] Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ.Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med. 2016; 33: 1493-8.

[3] Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, Jozic I. Diabetic wound-healing science. Medicina (Kaunas). 2021; 57: 1072.

[4] Yu X, Fu X, Yang J, Chen L, Leng F, Yang Z, et al. Glucose/ROS cascade-responsive ceria nanozymes for diabetic wound healing. Mater Today Bio. 2022; 15: 100308.

[5] Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014; 31: 817-36.

[6] Huang F, Lu X, Yang Y, Yang Y, Li Y, Kuai L, et al. Microenvironment-based diabetic foot ulcer Nanomedicine. Adv Sci (Weinh). 2023; 10: e2203308.

[7] National expert consensus on the diagnosis and surgical treatment of diabetic foot ulcers complicated with lower extremity vasculopathy (2024 version). Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2024; 40: 206-20.

[8] Poustchi F, Amani H, Ahmadian Z, Niknezhad SV, Mehrabi S, Santos HA, et al. Combination therapy of killing diseases by injectable hydrogels: from concept to medical applications. Adv Healthc Mater. 2021; 10: e2001571.

[9] Sun B, Wu F, Wang X, Song Q, Ye Z, Mohammadniaei M, et al. An optimally designed engineering exosome-reductive COF integrated Nanoagent for synergistically enhanced diabetic fester wound healing. Small. 2022; 18: e2200895.

[10] Yang D, Zhang W, Zhang H, Zhang F, Chen L, Ma L, et al. Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics. Theranostics. 2020; 10: 3684-707.

[11] Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021; 11: 3183-95.

[12] Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016; 6: 287-96.

[13] Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021; 19: 47.

[14] Belhadj Z, He B, Deng H, Song S, Zhang H, Wang X, et al. A combined "eat me/don’t eat me" strategy based on extracellular vesicles for anticancer nanomedicine. J Extracell Vesicles. 2020; 9: 1806444.

[15] Qiao Z, Wang X, Zhao H, Deng Y, Zeng W, Yang K, et al. The effectiveness of cell-derived exosome therapy for diabetic wound: a systematic review and meta-analysis. Ageing Res Rev. 2023; 85: 101858.

[16] Shen J, Zhao X, Zhong Y, Yang P, Gao P, Wu X, et al. Exosomal ncRNAs: the pivotal players in diabetic wound healing. Front Immunol. 2022; 13: 1005307.

[17] Lou R, Chen J, Zhou F, Wang C, Leung CH, Lin L. Exosome-cargoed microRNAs: potential therapeutic molecules for diabetic wound healing. Drug Discov Today. 2022; 27: 103323.

[18] Kučuk N, Primožič M, Knez Ž, Leitgeb M. Exosomes engineering and their roles as therapy delivery tools, therapeutic targets, and biomarkers. Int J Mol Sci. 2021; 22: 9543.

[19] Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA. 2023; 330: 62-75.

[20] Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021; 17: 400-20.

[21] Cao T, Hao T, Xiao D, Zhang WF, Ji P, Jia YH, et al. Effect and mechanism of human adipose-derived stem cell exosomes on diabetic peripheral neuropathy. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2024; 40: 240-8.

[22] Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016; 17: 917.

[23] Tellechea A, Leal E, Veves A, Carvalho E. Inflammatory and Angiogenic abnormalities in diabetic wound healing: role of neuropeptides and therapeutic perspectives. Open Circ Vasc J. 2010; 3: 43-55.

[24] Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006; 295: 547-53.

[25] Farber A.Chronic limb-threatening ischemia. N Engl J Med. 2018; 379: 171-80.

[26] Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the Management of Patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017; 135: e726-79.

[27] Morbach S, Furchert H, Gröblinghoff U, Hoffmeier H, Kersten K, Klauke GT, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012; 35: 2021-7.

[28] Chao CY, Cheing GL. Microvascular dysfunction in diabetic foot disease and ulceration. Diabetes Metab Res Rev. 2009; 25: 604-14.

[29] Du H, Li S, Lu J, Tang L, Jiang X, He X, et al. Single-cell RNA-seq and bulk-seq identify RAB17 as a potential regulator of angiogenesis by human dermal microvascular endothelial cells in diabetic foot ulcers. Burns Trauma. 2023; 11: tkad020.

[30] Saeed K, Esposito S, Akram A, Ascione T, Bal AM, Bassetti M, et al. Hot topics in diabetic foot infection. Int J Antimicrob Agents. 2020; 55: 105942.

[31] Leone A, Vitiello C, Gullì C, Sikora AK, Macagnino S, Colosimo C. Bone and soft tissue infections in patients with diabetic foot. Radiol Med. 2020; 125: 177-87.

[32] Pitocco D, Spanu T, Di Leo M, Vitiello R, Rizzi A, Tartaglione L, et al. Diabetic foot infections: a comprehensive overview. Eur Rev Med Pharmacol Sci. 2019; 23: 26-37.

[33] Sen P, Demirdal T, Emir B. Meta-analysis of risk factors for amputation in diabetic foot infections. Diabetes Metab Res Rev. 2019; 35: e3165.

[34] Xuan YH, Huang BB, Tian HS, Chi LS, Duan YM, Wang X, et al. High-glucose inhibits human fibroblast cell migration in wound healing via repression of bFGF-regulating JNK phosphorylation. PLoS One. 2014; 9: e108182.

[35] Lan CC, Liu IH, Fang AH, Wen CH, Wu CS. Hyperglycaemic conditions decrease cultured keratinocyte mobility: implications for impaired wound healing in patients with diabetes. Br J Dermatol. 2008; 159: 1103-15.

[36] Okano J, Kojima H, Katagi M, Nakagawa T, Nakae Y, Terashima T, et al. Hyperglycemia induces skin barrier dysfunctions with impairment of epidermal integrity in non-wounded skin of type 1 diabetic mice. PLoS One. 2016; 11: e0166215.

[37] Lee YB, Hwang HJ, Kim E, Lim SH, Chung CH, Choi EH. Hyperglycemia-activated 11β-hydroxysteroid dehydrogenase type 1 increases endoplasmic reticulum stress and skin barrier dysfunction. Sci Rep. 2023; 13: 9206.

[38] Aoki M, Murase T. Obesity-associated insulin resistance adversely affects skin function. PLoS One. 2019; 14: e0223528.

[39] Worsley AL, Lui DH, Ntow-Boahene W, Song W, Good L, Tsui J. The importance of inflammation control for the treatment of chronic diabetic wounds. Int Wound J. 2022; 20: 2346-59.

[40] Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci. 2004; 9: 283- 9.

[41] Kang HJ, Kumar S, D’elia A, Dash B, Nanda V, Hsia HC, et al. Self-assembled elastin-like polypeptide fusion protein coacervates as competitive inhibitors of advanced glycation end-products enhance diabetic wound healing. J Control Release. 2021; 333: 176-87.

[42] Joorabloo A, Liu T. Engineering exosome-based biomimetic nanovehicles for wound healing. J Control Release. 2023; 356: 463-80.

[43] Kalluri R, Lebleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367: eaau6977.

[44] Buratta S, Tancini B, Sagini K, Delo F, Chiaradia E, Urbanelli L, et al. Lysosomal exocytosis, exosome release and secretory autophagy: the Autophagic-and Endo-lysosomal systems go extracellular. Int J Mol Sci. 2020; 21: 2576.

[45] Patel N, Chin DD, Chung EJ. Exosomes in atherosclerosis, a double-edged sword: their role in disease pathogenesis and their potential as novel therapeutics. AAPS J. 2021; 23: 95.

[46] Vu NB, Nguyen HT, Palumbo R, Pellicano R, Fagoonee S, Pham PV. Stem cell-derived exosomes for wound healing: current status and promising directions. Minerva Med. 2021; 112: 384-400.

[47] Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255-89.

[48] Crescitelli R, Lässer C, Szabó TG, Kittel A, Eldh M, Dianzani I, et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles. 2013; 2: 20677.

[49] Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015; 13: 17-24.

[50] Mittelbrunn M, Sánchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol. 2012; 13: 328-35.

[51] Yu D, Mei Y, Wang L, Zhao Y, Fan X, Liang D, et al. Nano-seq analysis reveals different functional tendency between exosomes and microvesicles derived from hUMSC. Stem Cell Res Ther. 2023; 14: 272.

[52] Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019; 177: 428-445.e18.

[53] Royo F, Théry C, Falcón-Pérez JM, Nieuwland R, Witwer KW. Methods for separation and characterization of extracellular vesicles: results of a worldwide survey performed by the ISEV rigor and standardization subcommittee. Cells. 2020; 9: 1955.

[54] Livshits MA, Khomyakova E, Evtushenko EG, Lazarev VN, Kulemin NA, Semina SE, et al. Isolation of exosomes by differential centrifugation: theoretical analysis of a commonly used protocol. Sci Rep. 2015; 5: 17319.

[55] Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomedicine. 2020; 15: 6917-34.

[56] Gardiner C, Di Vizio D, Sahoo S, Théry C, Witwer KW, Wauben M, et al. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracell Vesicles. 2016; 5: 32945.

[57] Baranyai T, Herczeg K, Onódi Z, Voszka I, Módos K, Marton N, et al. Isolation of exosomes from blood plasma: qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods. PLoS One. 2015; 10: e0145686.

[58] Linares R, Tan S, Gounou C, Arraud N, Brisson AR. High-speed centrifugation induces aggregation of extracellular vesicles. J Extracell Vesicles. 2015; 4: 29509.

[59] Dong L, Zieren RC, Horie K, Kim CJ, Mallick E, Jing Y, et al. Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. J Extracell Vesicles. 2020; 10:e12044.

[60] Coumans FAW, Brisson AR, Buzas EI, Dignat-George F, Drees EEE, El-Andaloussi S, et al. Methodological guidelines to study extracellular vesicles. Circ Res. 2017; 120: 1632-48.

[61] Tian Y, Gong M, Hu Y, Liu H, Zhang W, Zhang M, et al. Quality and efficiency assessment of six extracellular vesicle isolation methods by nano-flow cytometry. J Extracell Vesicles. 2020; 9: 1697028.

[62] Lobb RJ, Becker M, Wen SW, Wong CS, Wiegmans AP, Leimgruber A, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles. 2015; 4: 27031.

[63] Rider MA, Hurwitz SN, Meckes DG Jr. ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles. Sci Rep. 2016; 6: 23978.

[64] Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; 30: Unit 3.22.

[65] Yang J, Wu S, Hou L, Zhu D, Yin S, Yang G, et al. Therapeutic effects of simultaneous delivery of nerve growth factor mRNA and protein via exosomes on cerebral ischemia. Mol Ther Nucleic Acids. 2020; 21: 512-22.

[66] Yang J, Zhang X, Chen X, Wang L, Yang G. Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Mol Ther Nucleic Acids. 2017; 7: 278-87.

[67] Zhao C, Busch DJ, Vershel CP, Stachowiak JC. Multifunctional transmembrane protein ligands for cell-specific targeting of plasma membrane-derived vesicles. Small. 2016; 12: 3837-48.

[68] Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015; 290: 8166-72.

[69] He C, Zheng S, Luo Y, Wang B. Exosome Theranostics: biology and translational medicine. Theranostics. 2018; 8: 237-55.

[70] Dooley K, Mcconnell RE, Xu K, Lewis ND, Haupt S, Youniss MR, et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol Ther. 2021; 29: 1729-43.

[71] Brown M, Stafford LJ, Onisk D, Joaquim T, Tobb A, Goldman L, et al. Snorkel: an epitope tagging system for measuring the surface expression of membrane proteins. PLoS One. 2013; 8: e73255.

[72] Stickney Z, Losacco J, Mcdevitt S, Zhang Z, Lu B. Development of exosome surface display technology in living human cells. Biochem Biophys Res Commun. 2016; 472: 53-9.

[73] Mukherjee A, Bisht B, Dutta S, Paul MK. Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy. Acta Pharmacol Sin. 2022; 43: 2759-76.

[74] Sato YT, Umezaki K, Sawada S, Mukai SA, Sasaki Y, Harada N, et al. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016; 6: 21933.

[75] Salunkhe S, Dheeraj BM, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Control Release. 2020; 326: 599-614.

[76] Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo JK, Choi C. Biodistribution of exosomes and engineering strategies for targeted delivery of therapeutic exosomes. Tissue Eng Regen Med. 2021; 18: 499-511.

[77] Parker CG, Pratt MR. Click chemistry in proteomic investigations. Cell. 2020; 180: 605-32.

[78] Takayama Y, Kusamori K, Nishikawa M. Click chemistry as a tool for cell engineering and drug delivery. Molecules. 2019; 24: 172.

[79] Yang X, Xie B, Peng H, Shi G, Sreenivas B, Guo J, et al. Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes. J Control Release. 2021; 329: 454-67.

[80] Kooijmans SAA, Fliervoet LAL, Van Der Meel R, Fens M, Heijnen HFG, Van Bergen En Henegouwen PMP, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016; 224: 77-85.

[81] Jafari D, Shajari S, Jafari R, Mardi N, Gomari H, Ganji F, et al. Designer exosomes: a new platform for biotechnology therapeutics. BioDrugs. 2020; 34: 567-86.

[82] Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun. 2018; 9: 1305.

[83] Sutaria DS, Jiang J, Elgamal OA, Pomeroy SM, Badawi M, Zhu X, et al. Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery. J Extracell Vesicles. 2017; 6: 1333882.

[84] Lv LH, Wan YL, Lin Y, Zhang W, Yang M, Li GL, et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem. 2012; 287: 15874-85.

[85] Torreggiani E, Roncuzzi L, Perut F, Zini N, Baldini N. Multimodal transfer of MDR by exosomes in human osteosarcoma. Int J Oncol. 2016; 49: 189-96.

[86] MaC P, Bussolati B, D’antico S, Ghiotto S, Tetta C, Brizzi MF, et al. Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs. Mol Ther Methods Clin Dev. 2019; 13: 133-44.

[87] Lee J, Lee H, Goh U, Kim J, Jeong M, Lee J, et al. Cellular engineering with membrane Fusogenic liposomes to produce functionalized extracellular vesicles. ACS Appl Mater Interfaces. 2016; 8: 6790-5.

[88] Kimiz-Gebologlu I, Oncel SS. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022; 347: 533-43.

[89] Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017; 38: 754-63.

[90] Sadeghi S, Tehrani FR, Tahmasebi S, Shafiee A, Hashemi SM. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023; 31: 145-69.

[91] Johnsen KB, Gudbergsson JM, Skov MN, Christiansen G, Gurevich L, Moos T, et al. Evaluation of electroporation-induced adverse effects on adipose-derived stem cell exosomes. Cytotechnology. 2016; 68: 2125-38.

[92] Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010; 18: 1606-14.

[93] Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015; 205: 35-44.

[94] Xi XM, Xia SJ, Lu R. Drug loading techniques for exosome-based drug delivery systems. Pharmazie. 2021; 76: 61-7.

[95] Fu S, Wang Y, Xia X, Zheng JC. Exosome engineering: current progress in cargo loading and targeted delivery. NanoImpact. 2020; 20: 100261.

[96] Podolak I, Galanty A, Sobolewska D. Saponins as cytotoxic agents: a review. Phytochem Rev. 2010; 9: 425-74.

[97] Cizmar P, Yuana Y. Detection and characterization of extracellular vesicles by transmission and Cryo-transmission electron microscopy. Methods Mol Biol. 2017; 1660: 221-32.

[98] Sitar S, Kejžar A, Pahovnik D, Kogej K, Tušek-Žnidarič M, Lenassi M, et al. Size characterization and quantification of exosomes by asymmetrical-flow field-flow fractionation. Anal Chem. 2015; 87: 9225-33.

[99] Van Der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost. 2014; 12: 1182-92.

[100] Deng F, Miller J. A review on protein markers of exosome from different bio-resources and the antibodies used for characterization. J Histotechnol. 2019; 42: 226-39.

[101] Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93: 137-88.

[102] Cheema S, Maisonneuve P, Zirie M, Jayyousi A, Alrouh H, Abraham A, et al. Risk factors for microvascular complications of diabetes in a high-risk Middle East population. J Diabetes Res. 2018; 2018: 8964027.

[103] Yang SL, Zhu LY, Han R, Sun LL, Li JX, Dou JT. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes. 2017; 9: 133-40.

[104] Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive Management of Cardiovascular Risk Factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022; 145: e722-59.

[105] Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020; 40: 1808-17.

[106] Armitage J. The safety of statins in clinical practice. Lancet. 2007; 370: 1781-90.

[107] Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J. 2022; 46: 817-8.

[108] Mineo C.Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res. 2020; 116: 1254-74.

[109] Li Z, Zhao P, Zhang Y, Wang J, Wang C, Liu Y, et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics. 2021; 11: 2953-65.

[110] Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, et al. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022; 109: 18-25.

[111] Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD.ANGPTL3 and Apolipoprotein C-III as novel lipid-lowering targets. Curr Atheroscler Rep. 2021; 23: 20.

[112] Olshan DS, Rader DJ. Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease? J Clin Lipidol. 2018; 12: 583-7.

[113] Baardman J, Verberk SGS, Van Der Velden S, Gijbels MJJ, Van Roomen C, Sluimer JC, et al. Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. Nat Commun. 2020; 11: 6296.

[114] Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society. Eur Heart J. 2021; 42: 4791-806.

[115] Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022; 43: 3198-208.

[116] Soehnlein O, Libby P. Targeting inflammation in atherosclerosis-from experimental insights to the clinic. Nat Rev Drug Discov. 2021; 20: 589-610.

[117] Ridker PM, Everett BM, Pradhan A, Macfadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019; 380: 752-62.

[118] Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat Rev Cardiol. 2022; 19: 228-49.

[119] Wu G, Zhang J, Zhao Q, Zhuang W, Ding J, Zhang C, et al. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic Heme biosynthesis for atherosclerosis treatment. Angew Chem Int Ed Engl. 2020; 59: 4068-74.

[120] Ma Q, Fan Q, Han X, Dong Z, Xu J, Bai J, et al. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy. J Control Release. 2021; 329: 445-53.

[121] Bouchareychas L, Duong P, Covarrubias S, Alsop E, Phu TA, Chung A, et al. Macrophage exosomes resolve atherosclerosis by regulating Hematopoiesis and inflammation via MicroRNA cargo. Cell Rep. 2020; 32: 107881.

[122] Yu M, Amengual J, Menon A, Kamaly N, Zhou F, Xu X, et al. Targeted Nanotherapeutics encapsulating liver X receptor agonist GW3965 enhance Antiatherogenic effects without adverse effects on hepatic lipid metabolism in Ldlr(−/−) mice. Adv Healthc Mater. 2017; 6: 1700313.

[123] Senders ML, Hernot S, Carlucci G, Van De Voort JC, Fay F, Calcagno C, et al. Nanobody-facilitated multiparametric PET/MRI phenotyping of atherosclerosis. JACC Cardiovasc Imaging. 2019; 12: 2015-26.

[124] Li C, Dou Y, Chen Y, Qi Y, Li L, Han S, et al. Site-specific MicroRNA-33 antagonism by pH-responsive Nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity. Adv Funct Mater. 2020; 30: 2002131.

[125] Qiao R, Qiao H, Zhang Y, Wang Y, Chi C, Tian J, et al. Molecular imaging of vulnerable atherosclerotic plaques in vivo with Osteopontin-specific Upconversion Nanoprobes. ACS Nano. 2017; 11: 1816-25.

[126] Nie S, Zhang J, Martinez-Zaguilan R, Sennoune S, Hossen MN, Lichtenstein AH, et al. Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles. J Control Release. 2015; 220: 61-70.

[127] Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, Young MJ, et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano. 2011; 5: 2493-502.

[128] Bowling FL, Rashid ST, Boulton AJ. Preventing and treating foot complications associated with diabetes mellitus. Nat Rev Endocrinol. 2015; 11: 606-16.

[129] Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005; 39: 733-42.

[130] Li X, Xie X, Lian W, Shi R, Han S, Zhang H, et al. Exosomes from adipose-derived stem cells overexpressing Nrf2 accelerate cutaneous wound healing by promoting vascularization in a diabetic foot ulcer rat model. Exp Mol Med. 2018; 50: 1-14.

[131] Zhang J, Chen C, Hu B, Niu X, Liu X, Zhang G, et al. Exosomes derived from human endothelial progenitor cells accelerate cutaneous wound healing by promoting angiogenesis through Erk1/2 Signaling. Int J Biol Sci. 2016; 12: 1472-87.

[132] Yan T, Liu Y, Cui K, Hu B, Wang F, Zou L. MicroRNA-126 regulates EPCs function: implications for a role of miR-126 in preeclampsia. J Cell Biochem. 2013; 114: 2148-59.

[133] Chistiakov DA, Orekhov AN, Bobryshev YV. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. J Mol Cell Cardiol. 2016; 97: 47-55.

[134] Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008; 15: 272-84.

[135] Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol. 2012; 53: 64-72.

[136] Ma J, Zhang Z, Wang Y, Shen H. Investigation of miR-126-3p loaded on adipose stem cell-derived exosomes for wound healing of full-thickness skin defects. Exp Dermatol. 2022; 31: 362-74.

[137] Tao SC, Guo SC, Li M, Ke QF, Guo YP, Zhang CQ. Chitosan wound dressings incorporating exosomes derived from MicroRNA-126-overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model. Stem Cells Transl Med. 2017; 6: 736-47.

[138] Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019; 5: 42.

[139] Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993; 43: 817-24.

[140] Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27: 620-8.

[141] Lai YR, Huang CC, Chiu WC, Liu RT, Tsai NW, Wang HC, et al. Close relationship between cardiovagal function and sural sensory nerve action potential in type 2 diabetes. Clin Neurophysiol. 2019; 130: 1160-5.

[142] Huang J, Sun R, Feng S, He J, Fei F, Gao H, et al. Sensitive analysis and pharmacokinetic study of epalrestat in C57BL/6J mice. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1055-1056: 98-103.

[143] Brufani M, Figliola R. (R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy. Acta Biomed. 2014; 85: 108-15.

[144] Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016; 16: 29.

[145] Hinder LM, Murdock BJ, Park M, Bender DE, O’brien PD, Rumora AE, et al. Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: an inflammatory story. Exp Neurol. 2018; 305: 33-43.

[146] Zhou JY, Zhang Z, Qian GS. Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic. Cell Death Discov. 2016; 2: 16055.

[147] Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011; 108: 1340-7.

[148] Zhang C, Huang Y, Ouyang F, Su M, Li W, Chen J, et al. Extracellular vesicles derived from mesenchymal stem cells alleviate neuroinflammation and mechanical allodynia in interstitial cystitis rats by inhibiting NLRP3 inflammasome activation. J Neuroinflammation. 2022; 19: 80.

[149] Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lässer C, Segaliny AI, et al. Stem cell-derived exosomes as Nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano. 2019; 13: 6670-88.

[150] Qing L, Chen H, Tang J, Jia X. Exosomes and their MicroRNA cargo: new players in peripheral nerve regeneration. Neurorehabil Neural Repair. 2018; 32: 765-76.

[151] Fan B, Li C, Szalad A, Wang L, Pan W, Zhang R, et al. Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes. Diabetologia. 2020; 63: 431-43.

[152] Fan B, Chopp M, Zhang ZG, Liu XS. Treatment of diabetic peripheral neuropathy with engineered mesenchymal stromal cell-derived exosomes enriched with microRNA-146a provide amplified therapeutic efficacy. Exp Neurol. 2021; 341: 113694.

[153] Zhang Y, Chopp M, Liu XS, Katakowski M, Wang X, Tian X, et al. Exosomes derived from mesenchymal stromal cells promote axonal growth of cortical neurons. Mol Neurobiol. 2017; 54: 2659-73.

[154] Oh B, George P. Conductive polymers to modulate the post-stroke neural environment. Brain Res Bull. 2019; 148: 10-7.

[155] Singh A, Raghav A, Shiekh PA, Kumar A. Transplantation of engineered exosomes derived from bone marrow mesenchymal stromal cells ameliorate diabetic peripheral neuropathy under electrical stimulation. Bioact Mater. 2021; 6: 2231-49.

[156] Zhang F, Zhang M, Liu S, Li C, Ding Z, Wan T, et al. Application of hybrid electrically conductive hydrogels promotes peripheral nerve regeneration. Gels. 2022; 8: 41.

[157] Cai Y, Huang Q, Wang P, Ye K, Zhao Z, Chen H, et al. Conductive hydrogel conduits with growth factor gradients for peripheral nerve repair in diabetics with non-suture tape. Adv Healthc Mater. 2022; 11: e2200755.

[158] Liu C, Fan L, Tian Z, Wen H, Zhou L, Guan P, et al. Self-curling electroconductive nerve dressing for enhancing peripheral nerve regeneration in diabetic rats. Bioact Mater. 2021; 6: 3892-903.

[159] Yang Q, Su S, Liu S, Yang S, Xu J, Zhong Y, et al. Exosomes-loaded electroconductive nerve dressing for nerve regeneration and pain relief against diabetic peripheral nerve injury. Bioact Mater. 2023; 26: 194-215.

[160] Wang Y, Yu T, Hu F. Hypocapnia stimuli-responsive engineered exosomes delivering miR-218 facilitate sciatic nerve regeneration. Front Bioeng Biotechnol. 2022; 10: 825146.

[161] Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007; 13: 119-26.

[162] Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012; 68: 1243-55.

[163] Gao W, Chen Y, Zhang Y, Zhang Q, Zhang L. Nanoparticle-based local antimicrobial drug delivery. Adv Drug Deliv Rev. 2018; 127: 46-57.

[164] Watkins KE, Unnikrishnan M. Evasion of host defenses by intracellular Staphylococcus aureus. Adv Appl Microbiol. 2020; 112: 105-41.

[165] Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. Aureus. Nature. 2015; 527: 323-8.

[166] Kumar NG, Nieto V, Kroken AR, Jedel E, Grosser MR, Hallsten ME, et al. Pseudomonas aeruginosa can diversify after host cell invasion to establish multiple intracellular niches. MBio. 2022; 13: e0274222.

[167] Maure A, Robino E, Van Der Henst C. The intracellular life of Acinetobacter baumannii. Trends Microbiol. 2023; 31: 1238-50.

[168] Wanford JJ, Hames RG, Carreno D, Jasiunaite Z, Chung WY, Arena F, et al. Interaction of Klebsiella pneumoniae with tissue macrophages in a mouse infection model and ex-vivo pig organ perfusions: an exploratory investigation. Lancet Microbe. 2021; 2: e695-703.

[169] Hommes JW, Surewaard BGJ. Intracellular habitation of Staphylococcus aureus: molecular mechanisms and prospects for antimicrobial therapy. Biomedicines. 2022; 10: 1880.

[170] Stacey HJ, Clements CS, Welburn SC, Jones JD. The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis. Acta Diabetol. 2019; 54: 907-21.

[171] Baxt LA, Garza-Mayers AC, Goldberg MB. Bacterial subversion of host innate immune pathways. Science. 2013; 34:: 697-701.

[172] Yang X, Shi G, Guo J, Wang C, He Y. Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus. Int J Nanomedicine. 2018; 13: 8095-1004.

[173] Mckelvey KJ, Powell KL, Ashton AW, Morris JM, Mccracken SA. Exosomes: mechanisms of uptake. J Circ Biomark. 2015; 4: 7.

[174] Fraunholz M, Sinha B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol. 2012; 2: 43.

[175] Price JV, Russo D, Ji DX, Chavez RA, Dipeso L, Lee AY, et al. IRG1 and inducible nitric oxide synthase act redundantly with other interferon-gamma-induced factors to restrict intracellular replication of legionella pneumophila. MBio. 2019; 10: e02629-19.

[176] Luozhong S, Yuan Z, Sarmiento T, Chen Y, Gu W, Mccurdy C, et al. Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs. Nano Lett. 2022; 22: 8304-11.

[177] Kraal G, Van Der Laan LJ, Elomaa O, Tryggvason K. The macrophage receptor MARCO. Microbes Infect. 2000; 2: 313-6.

[178] Wang Y, Zhang Y, Wang Z, Zhang J, Qiao RR, Xu M, et al. Optical/MRI dual-modality imaging of M1 macrophage polarization in atherosclerotic plaque with MARCO-targeted upconversion luminescence probe. Biomaterials. 2019; 219: 119378.

[179] Hajiahmadi F, Alikhani MY, Shariatifar H, Arabestani MR, Ahmadvand D. The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistant Staphylococcus aureus infected skin wounds in mice. Int J Nanomedicine. 2019; 14: 5943-55.

[180] Qi G, Li L, Yu F, Wang H. Vancomycin-modified mesoporous silica nanoparticles for selective recognition and killing of pathogenic gram-positive bacteria over macrophage-like cells. ACS Appl Mater Interfaces. 2013; 5: 10874-81.

[181] Choi KH, Lee HJ, Park BJ, Wang KK, Shin EP, Park JC, et al. Photosensitizer and vancomycin-conjugated novel multifunctional magnetic particles as photoinactivation agents for selective killing of pathogenic bacteria. Chem Commun (Camb). 2012; 48: 4591-3.

[182] Choi SK, Myc A, Silpe JE, Sumit M, Wong PT, Mccarthy K, et al. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano. 2013; 7: 214-28.

[183] Huang PJ, Tay LL, Tanha J, Ryan S, Chau LK. Single-domain antibody-conjugated nanoaggregate-embedded beads for targeted detection of pathogenic bacteria. Chemistry. 2009; 15: 9330-4.

[184] Tay LL, Huang PJ, Tanha J, Ryan S, Wu X, Hulse J, et al. Silica encapsulated SERS nanoprobe conjugated to the bacteriophage tailspike protein for targeted detection of salmonella. Chem Commun (Camb). 2012; 48: 1024-6.

[185] Song MY, Jurng J, Park YK, Kim BC. An aptamer cocktail-functionalized photocatalyst with enhanced antibacterial efficiency towards target bacteria. J Hazard Mater. 2016; 318: 247-54.

[186] Duan N, Wu S, Chen X, Huang Y, Xia Y, Ma X, et al. Selection and characterization of aptamers against salmonella typhimurium using whole-bacterium systemic evolution of ligands by exponential enrichment (SELEX). J Agric Food Chem. 2013; 61: 3229-34.

[187] Wolfram J, Ferrari M. Clinical cancer Nanomedicine. Nano Today. 2019; 25: 85-98.

[188] Yan J, Fei W, Song Q, Zhu Y, Bu N, Wang L, et al. Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application. Drug Deliv. 2022; 29: 2296-319.

[189] Liu C, Zhang W, Li Y, Chang J, Tian F, Zhao F, et al. Microfluidic sonication to assemble exosome membrane-coated nanoparticles for immune evasion-mediated targeting. Nano Lett. 2019; 19: 7836-44.

[190] Zhang W, Ngo L, Tsao SC, Liu D, Wang Y. Engineered cancer-derived small extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast cancer. ACS Appl Mater Interfaces. 2023; 15: 16420-33.

[191] Versey Z, Da Cruz Nizer WS, Russell E, Zigic S, Dezeeuw KG, Marek JE, et al. Biofilm-innate immune Interface: contribution to chronic wound formation. Front Immunol. 2021; 12: 648554.

[192] Wang J, Yao Y, Chen X, Wu J, Gu T, Tang X. Host derived exosomes-pathogens interactions: potential functions of exosomes in pathogen infection. Biomed Pharmacother. 2018; 108: 1451-9.

[193] Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020; 19: 160.

[194] Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br J Dermatol. 2015; 173: 370-8.

[195] Zhao R, Liang H, Clarke E, Jackson C, Xue M. Inflammation in chronic wounds. Int J Mol Sci. 2016; 17: 2085.

[196] Acosta JB, Del Barco DG, Vera DC, Savigne W, Lopez-Saura P, Guillen Nieto G, et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J. 2008; 5: 530-9.

[197] Grosick R, Alvarado-Vazquez PA, Messersmith AR, Romero-Sandoval EA. High glucose induces a priming effect in macrophages and exacerbates the production of pro-inflammatory cytokines after a challenge. J Pain Res. 2018; 11: 1769-78.

[198] Mirza R, Koh TJ. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine. 2011; 56: 256-64.

[199] Raziyeva K, Kim Y, Zharkinbekov Z, Kassymbek K, Jimi S, Saparov A. Immunology of acute and chronic wound healing. Biomol Ther. 2021; 11: 700.

[200] Kuai L, Xiang YW, Chen QL, Ru Y, Yin SY, Li W, et al. PD-L1 triggered by binding eIF3I contributes to the amelioration of diabetes-associated wound healing defects by regulating IRS4. J Invest Dermatol. 2022; 142: 220-231.e8.

[201] Su D, Tsai HI, Xu Z, Yan F, Wu Y, Xiao Y, et al. Exosomal PD-L1 functions as an immunosuppressant to promote wound healing. J Extracell Vesicles. 2019; 9: 1709262.

[202] Louiselle AE, Niemiec SM, Zgheib C, Liechty KW. Macrophage polarization and diabetic wound healing. Transl Res. 2021; 236: 109-16.

[203] Morey M, O’gaora P, Pandit A, Hélary C. Hyperglycemia acts in synergy with hypoxia to maintain the pro-inflammatory phenotype of macrophages. PLoS One. 2019; 14: e0220577.

[204] Pavlou S, Lindsay J, Ingram R, Xu H, Chen M. Sustained high glucose exposure sensitizes macrophage responses to cytokine stimuli but reduces their phagocytic activity. BMC Immunol. 2018; 19: 24.

[205] Basu Mallik S, Jayashree BS, Shenoy RR. Epigenetic modulation of macrophage polarization-perspectives in diabetic wounds. J Diabetes Complicat. 2018; 32: 524-30.

[206] Wolf SJ, Melvin WJ, Gallagher K. Macrophage-mediated inflammation in diabetic wound repair. Semin Cell Dev Biol. 2021; 119: 111-8.

[207] Boniakowski AE, Kimball AS, Jacobs BN, Kunkel SL, Gallagher KA. Macrophage-mediated inflammation in normal and diabetic wound healing. J Immunol. 2017; 199: 17-24.

[208] Li Z, Zhou X, Gao X, Bai D, Dong Y, Sun W, et al. Fusion protein engineered exosomes for targeted degradation of specific RNAs in lysosomes: a proof-of-concept study. J Extracell Vesicles. 2020; 9: 1816710.

[209] Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014; 10: 520-9.

[210] Liu W, Yu M, Xie D, Wang L, Ye C, Zhu Q, et al. Melatonin-stimulated MSC-derived exosomes improve diabetic wound healing through regulating macrophage M1 and M2 polarization by targeting the PTEN/AKT pathway. Stem Cell Res Ther. 2020; 11: 259.

[211] Theocharidis G, Thomas BE, Sarkar D, Mumme HL, Pilcher WJR, Dwivedi B, et al. Single cell transcriptomic landscape of diabetic foot ulcers. Nat Commun. 2022; 13: 181.

[212] Jetten N, Roumans N, Gijbels MJ, Romano A, Post MJ, De Winther MP, et al. Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. PLoS One. 2014; 9: e102994.

[213] Dreymueller D, Denecke B, Ludwig A, Jahnen-Dechent W. Embryonic stem cell-derived M2-like macrophages delay cutaneous wound healing. Wound Repair Regen. 2013; 21: 44-54.

[214] Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomol Ther. 2022; 12: 542.

[215] Hu H, Jiang H, Ren H, Hu X, Wang X, Han C. AGEs and chronic subclinical inflammation in diabetes: disorders of immune system. Diabetes Metab Res Rev. 2015; 31: 127-37.

[216] Sanajou D, Ghorbani Haghjo A, Argani H, Aslani S. AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions. Eur J Pharmacol. 2018; 833: 158-64.

[217] Chen SA, Chen HM, Yao YD, Hung CF, Tu CS, Liang YJ. Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products. Eur J Pharm Sci. 2012; 47: 875-83.

[218] Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol. 2008; 35: 329-34.

[219] Xu J, Bai S, Cao Y, Liu L, Fang Y, Du J, et al. miRNA-221-3p in endothelial progenitor cell-derived exosomes accelerates skin wound healing in diabetic mice. Diabetes Metab Syndr Obes. 2020; 13: 1259-70.

[220] Kim M, Lee Y, Lee M. Hypoxia-specific anti-RAGE exosomes for nose-to-brain delivery of anti-miR-181a oligonucleotide in an ischemic stroke model. Nanoscale. 2021; 13: 14166-78.

[221] Kim G, Lee Y, Ha J, Han S, Lee M. Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation. J Control Release. 2021; 330: 684-95.

[222] Vollono L, Falconi M, Gaziano R, Iacovelli F, Dika E, Terracciano C, et al. Potential of curcumin in skin disorders. Nutrients. 2019; 11: 2169.

[223] Rousselle P, Montmasson M, Garnier C. Extracellular matrix contribution to skin wound re-epithelialization. Matrix Biol. 2019; 75-76: 12-26.

[224] Ando Y, Jensen PJ. Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration. J Invest Dermatol. 1993; 100: 633-9.

[225] Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol. 2007; 127: 998-1008.

[226] Shakhakarmi K, Seo JE, Lamichhane S, Thapa C, Lee S. EGF, a veteran of wound healing: highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies. Arch Pharm Res. 2023; 46: 299-322.

[227] Liu Y, Liu Y, Deng J, Li W, Nie X. Fibroblast growth factor in diabetic foot ulcer: progress and therapeutic prospects. Front Endocrinol (Lausanne). 2021; 12: 744868.

[228] Ead JK, Armstrong DG. Granulocyte-macrophage colony-stimulating factor: conductor of the wound healing orchestra? Int Wound J. 2023; 20: 1229-34.

[229] Guan N, Liu Z, Zhao Y, Li Q, Wang Y. Engineered biomaterial strategies for controlling growth factors in tissue engineering. Drug Deliv. 2020; 27: 1438-51.

[230] Seeger MA, Paller AS. The roles of growth factors in keratinocyte migration. Adv Wound Care (New Rochelle). 2015; 4: 213-24.

[231] Shi A, Li J, Qiu X, Sabbah M, Boroumand S, Huang TC, et al. TGF-β loaded exosome enhances ischemic wound healing in vitro and in vivo. Theranostics. 2021; 11: 6616-31.

[232] Guo SC, Tao SC, Yin WJ, Qi X, Yuan T, Zhang CQ. Exosomes derived from platelet-rich plasma promote the re-epithelialization of chronic cutaneous wounds via activation of YAP in a diabetic rat model. Theranostics. 2017; 7: 81-96.

[233] Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med. 2020; 217: e20190103.

[234] Lichtman MK, Otero-Vinas M, Falanga V. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen. 2016; 24: 215-22.

[235] Ye J, Kang Y, Sun X, Ni P, Wu M, Lu S. MicroRNA-155 inhibition promoted wound healing in diabetic rats. Int J Low Extrem Wounds. 2017; 16: 74-84.

[236] Moura J, Sørensen A, Leal EC, Svendsen R, Carvalho L, Willemoes RJ, et al. microRNA-155 inhibition restores fibroblast growth factor 7 expression in diabetic skin and decreases wound inflammation. Sci Rep. 2019; 9: 5836.

[237] Gondaliya P, Sayyed AA, Bhat P, Mali M, Arya N, Khairnar A, et al. Mesenchymal stem cell-derived exosomes loaded with miR-155 inhibitor ameliorate diabetic wound healing. Mol Pharm. 2022; 19: 1294-308.

[238] Sun D, Guo K, Liu N, Li Y, Li Y, Hu Y, et al. Peptide RL-QN15 promotes wound healing of diabetic foot ulcers through p38 mitogen-activated protein kinase and smad3/miR-4482-3p/vascular endothelial growth factor B axis. Burns Trauma. 2023; 11: tkad035.

[239] Qin P, Meng Y, Yang Y, Gou X, Liu N, Yin S, et al. Mesoporous polydopamine nanoparticles carrying peptide RL-QN15 show potential for skin wound therapy. J Nanobiotechnology. 2021; 19: 309.

[240] KaU G, Fuchs E. Skin and its regenerative powers: an alliance between stem cells and their niche. Dev Cell. 2017; 43: 387-401.

[241] Simpson CL, Patel DM, Green KJ. Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis. Nat Rev Mol Cell Biol. 2011; 12: 565-80.

[242] Solanas G, Benitah SA. Regenerating the skin: a task for the heterogeneous stem cell pool and surrounding niche. Nat Rev Mol Cell Biol. 2013; 14: 737-48.

[243] Donati G, Watt FM. Stem cell heterogeneity and plasticity in epithelia. Cell Stem Cell. 2015; 16: 465-76.

[244] Yang R, Liu F, Wang J, Chen X, Xie J, Xiong K. Epidermal stem cells in wound healing and their clinical applications. Stem Cell Res Ther. 2019; 10: 229.

[245] Mascré G, Dekoninck S, Drogat B, Youssef KK, Brohé S, Sotiropoulou PA, et al. Distinct contribution of stem and progenitor cells to epidermal maintenance. Nature. 2012; 489: 257-62.

[246] Liu Z, Yang Y, Ju J, Zhang G, Zhang P, Ji P, et al. miR-100-5p promotes epidermal stem cell proliferation through targeting MTMR3 to activate PIP3/AKT and ERK Signaling pathways. Stem Cells Int. 2022; 2022: 1474273.

[247] Wang P, Theocharidis G, Vlachos IS, Kounas K, Lobao A, Shu B, et al. Exosomes derived from epidermal stem cells improve diabetic wound healing. J Invest Dermatol. 2022; 142: 2508-2517.e13.

[248] Ocansey DKW, Zhang L, Wang Y, Yan Y, Qian H, Zhang X, et al. Exosome-mediated effects and applications in inflammatory bowel disease. Biol Rev Camb Philos Soc. 2020; 95: 1287-307.

[249] Chu M, Wang H, Bian L, Huang J, Wu D, Zhang R, et al. Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia. Stem Cell Rev Rep. 2022; 18: 2152-63.

[250] Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020; 21: 1835.

[251] Dewanjee S, Das S, Das AK, Bhattacharjee N, Dihingia A, Dua TK, et al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur J Pharmacol. 2018; 833: 472-523.

[252] Wang Y, Zhu J, Chen J, Xu R, Groth T, Wan H, et al. The Signaling pathways induced by exosomes in promoting diabetic wound healing: a mini-review. Curr Issues Mol Biol. 2022; 44: 4960-76.

[253] Jiang M, Jiang X, Li H, Zhang C, Zhang Z, Wu C, et al. The role of mesenchymal stem cell-derived EVs in diabetic wound healing. Front Immunol. 2023; 14: 1136098.

[254] Sun M, Yang J, Fan Y, Zhang Y, Sun J, Hu M, et al. Beyond extracellular vesicles: hybrid membrane Nanovesicles as emerging advanced tools for biomedical applications. Adv Sci (Weinh). 2023; 10: e2303617.

[255] Ju Y, Hu Y, Yang P, Xie X, Fang B. Extracellular vesicle-loaded hydrogels for tissue repair and regeneration. Mater Today Bio. 2023; 18: 100522.

[256] Zhao J, Qiu P, Wang Y, Wang Y, Zhou J, Zhang B, et al. Chitosan-based hydrogel wound dressing: from mechanism to applications, a review. Int J Biol Macromol. 2023; 244: 125250.

[257] Xiao S, Xiao C, Miao Y, Wang J, Chen R, Fan Z, et al. Human acellular amniotic membrane incorporating exosomes from adipose-derived mesenchymal stem cells promotes diabetic wound healing. Stem Cell Res Ther. 2021; 12: 255.

[258] Yuan M, Liu K, Jiang T, Li S, Chen J, Wu Z, et al. Gel-MA/PEGDA microneedles patch loaded with HUVECs-derived exosomes and Tazarotene promote diabetic wound healing. J Nanobiotechnology. 2022; 20: 147.

[259] Wang M, Wang C, Chen M, Xi Y, Cheng W, Mao C, et al. Efficient angiogenesis-based diabetic wound healing/skin reconstruction through bioactive antibacterial adhesive ultraviolet shielding Nanodressing with exosome release. ACS Nano. 2019; 13: 10279-93.

[260] Li Q, Hu W, Huang Q, Yang J, Li B, Ma K, et al. MiR146a-loaded engineered exosomes released from silk fibroin patch promote diabetic wound healing by targeting IRAK1. Signal Transduct Target Ther. 2023; 8: 62.

[261] Sun M, Li Q, Yu H, Cheng J, Wu N, Shi W, et al. Cryo-self-assembled silk fibroin sponge as a biodegradable platform for enzyme-responsive delivery of exosomes. Bioact Mater. 2022; 8: 505-14.

[262] Poongodi R, Chen YL, Yang TH, Huang YH, Yang KD, Lin HC, et al. Bio-scaffolds as cell or exosome carriers for nerve injury repair. Int J Mol Sci. 2021; 22: 13347.

[263] Jiang P, Li Q, Luo Y, Luo F, Che Q, Lu Z, et al. Current status and progress in research on dressing management for diabetic foot ulcer. Front Endocrinol (Lausanne). 2023; 14: 1221705.

[264] Hu P, Armato U, Freddi G, Chiarini A, Dal Prà I. Human keratinocytes and fibroblasts Co-cultured on silk fibroin scaffolds Exosomally Overrelease Angiogenic and growth factors. Cells. 2023; 12: 1827.

[265] Hu P, Chiarini A, Wu J, Wei Z, Armato U, Dal Prà I. Adult human vascular smooth muscle cells on 3D silk fibroin nonwovens release exosomes enriched in Angiogenic and growth-promoting factors. Polymers (Basel). 2022; 14: 697.

[266] Hu P, Chiarini A, Wu J, Freddi G, Nie K, Armato U, et al. Exosomes of adult human fibroblasts cultured on 3D silk fibroin nonwovens intensely stimulate neoangiogenesis. Burns Trauma. 2021; 9: tkab003.

[267] Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017; 110: 104-9.

[268] Taylor DD, Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 2015; 87: 3-10.

[269] Debbi L, Guo S, Safina D, Levenberg S. Boosting extracellular vesicle secretion. Biotechnol Adv. 2022; 59: 107983.

[270] Wu M, Ouyang Y, Wang Z, Zhang R, Huang PH, Chen C, et al. Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proc Natl Acad Sci USA. 2017; 114: 10584-9.

[271] Chen Y, Zhu Q, Cheng L, Wang Y, Li M, Yang Q, et al. Exosome detection via the ultrafast-isolation system: EXODUS. Nat Methods. 2021; 18: 212-8.

[272] Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng. 2020; 4: 69-83.

[273] Ding L, Yang X, Gao Z, Effah CY, Zhang X, Wu Y, et al. A holistic review of the state-of-the-art microfluidics for exosome separation: an overview of the current status, existing obstacles, and future outlook. Small. 2021; 17:e2007174.

[274] Whiteside TL.Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016; 74: 103-41.